Erectile dysfunction (ED) is defined as the inability to attain and/or maintain a penile erection. The first introduction of intracavernosal injection (ICI) for the treatment of erectile failure was in 1982 by Virag who reported the positive effects of papaverine on erectile tissue, followed by Brindley concurrently conducting research on ICI therapy with alpha-blockade. ICI remains a viable option for the treatment of ED, even after FDA approval of phosphodiesterase type 5 inhibitors in 1998. The American Urological Association (AUA) and the European Association of Urology (EAU) both recommend ICI as a second-line therapy for the treatment of ED. We herein provide an overview of the current state of ICI therapy for the treatment of ED.
We performed a literature review from 1977-2022, using PubMed and the current AUA and EAU guidelines to discuss the current state of ICI for the treatment of ED.
Although other oral agents are considered first line for the treatment of ED, the current guidelines and literature demonstrate that ICI is a safe and effective option for patients; however, careful patient selection and counseling should be performed to maximize the effectiveness and safety of this ED treatment.
Expert opinion on pharmacotherapy. 2023 Apr 20 [Epub ahead of print]
Bobo W Elena, Melchiode Zachary, Pavaluri Haritha, Bobo A Graham, Hellstrom J G Wayne
Tulane University School of Medicine, Department of Urology, Section of Andrology, New Orleans, Louisiana, United States of America., University of Queensland, Ochsner Clinical School, New Orleans, Louisiana, United States of America.